Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations (Q43894262)

27 November 2017

title

Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations (English)

1 reference

27 November 2017

0 references

1 reference

8

Ralph H Hruban

1 reference

27 November 2017

5

Anirban Maitra

1 reference

27 November 2017

7

David S Klimstra

1 reference

27 November 2017

4

Jordan Winter

1 reference

27 November 2017

6

N Volkan Adsay

1 reference

27 November 2017

1

Dengfeng Cao

1 reference

27 November 2017

Cristina Antonescu

2

1 reference

27 November 2017

Grace Wong

series ordinal

3

1 reference

27 November 2017

publication date

16 June 2006

1 reference

27 November 2017

1 reference

27 November 2017

volume

19

1 reference

27 November 2017

issue

9

1 reference

27 November 2017

page(s)

1157-1163

1 reference

Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Solid pseudopapillary tumors of the pancreas: review of 718 patients reported in English literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Regulation and targets of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

CD117 (KIT): a diverse protein with selective applications in surgical pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Interstitial cells of Cajal in pancreas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

PDGFRA activating mutations in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Sequence analysis and high-throughput immunohistochemical profiling of KIT (CD 117) expression in uveal melanoma using tissue microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Prevalence of KIT expression in human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Targeted therapy with imatinib: hits and misses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Thymic carcinoma with overexpression of mutated KIT and the response to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Gastrointestinal stromal tumor of the pancreas: case report with documentation of KIT gene mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

Solid-pseudopapillary tumor of the pancreas: its origin revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

7 January 2021

KIT expression in angiosarcomas and fetal endothelial cells: lack of mutations of exon 11 and exon 17 of C-kit

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

7 January 2021

c-kit overexpression in chromophobe renal cell carcinoma is not associated with c-kit mutation of exons 9 and 11

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

7 January 2021

Diagnosis of gastrointestinal stromal tumors: A consensus approach

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

7 January 2021

Papillary-cystic neoplasm of the pancreas. A clinicopathologic study concerning the tumor aging and malignancy of nine cases

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

7 January 2021

Cellular hamartoma resembling gastrointestinal stromal tumor: a solid tumor of the pancreas expressing c-kit (CD117)

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.3800647

7 January 2021

10.1038/MODPATHOL.3800647

Identifiers

DOI

1 reference

Dimensions Publication ID

27 November 2017

1049358948

0 references

1 reference